Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Long-term ultra-low-dose aspirin therapy and platelet function.

N Chetty, P M Atkinson, B A Bradlow

    South African Medical Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde
    |August 31, 1985
    PubMed
    Summary

    Ultra-low-dose aspirin (20 mg/d) showed reduced platelet aggregation inhibition after 4 weeks compared to 162 mg/d. The 20 mg dose is insufficient for sustained antiplatelet effects in healthy individuals.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Influence of landscape on the distribution of inflammatory bowel disease in England and Wales.

    BMC public health·2026
    Same author

    Intra-host SARS-CoV-2 diversity in immunocompromised people living with HIV provides insight into the evolutionary trajectory of SARS-CoV-2.

    Journal of virology·2025
    Same author

    Building consensus on clinical outcome assessments for BCI devices. A summary of the 10th BCI society meeting 2023 workshop.

    Journal of neural engineering·2024
    Same author

    Development of a permanent vacuum hollow prism air refractometer for use in dimensional metrology.

    Scientific reports·2021
    Same author

    Breast cancer cell-induced platelet activation is compounded by tamoxifen and anastrozole in vitro.

    Thrombosis research·2019
    Same author

    Band gap engineering of a MoS<sub>2</sub> monolayer through oxygen alloying: an ab initio study.

    Nanotechnology·2018

    Area of Science:

    • Pharmacology
    • Cardiovascular Medicine
    • Hematology

    Background:

    • Aspirin is widely used for its antiplatelet effects.
    • Understanding the efficacy of ultra-low doses is crucial for optimizing therapeutic strategies.
    • Platelet aggregation and thromboxane B2 (TXB2) production are key markers of aspirin's action.

    Purpose of the Study:

    • To compare the effects of two ultra-low aspirin doses (162 mg/d and 20 mg/d) on platelet function.
    • To determine the duration of antiplatelet effect for a 20 mg/d aspirin dose.
    • To assess the threshold dose for maintaining adequate platelet inhibition.

    Main Methods:

    • Two groups of healthy subjects received either 162 mg/d or 20 mg/d of aspirin for 4 weeks.
    • Platelet aggregation and thromboxane B2 (TXB2) production were measured throughout the study period.

    Related Experiment Videos

  • Dose escalation to 40 mg/d was performed for subjects showing diminished response.

    • Main Results:

    • Both aspirin doses initially inhibited platelet aggregation and TXB2 production similarly.
    • After 4 weeks, significantly less platelet aggregation inhibition was observed in the 20 mg/d group.
    • Two subjects on 20 mg/d showed 'escape' from aspirin's effect, responding to 40 mg/d.

    Conclusions:

    • A daily aspirin dose of 20 mg is insufficient to maintain adequate platelet function inhibition in normal subjects over time.
    • Higher doses may be required for sustained antiplatelet therapy, even at the lower end of the therapeutic range.
    • Individual variability in response to low-dose aspirin necessitates careful consideration of dosage and monitoring.